Mitochondrial Biogenesis Inhibitors for Anticancer Therapy: A Review of Recent Patents

Author(s): Jinzheng Wang, Xiaoan Wen, Jun Liu, Hongbin Sun

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 11 , Issue 3 , 2016

Become EABM
Become Reviewer

Abstract:

Recent studies show that enhanced mitochondrial biogenesis can “fuel” the cancer cells to grow and migrate. It is therefore proposed that inhibiting the mitochondrial biogenesis could be a new approach to cancer therapy. This review summarizes recent patents and papers in the development of small molecule inhibitors of key regulators responsible for tumor mitochondrial biogenesis, including PPARγcoactivator-1α(PGC-1α), PPARγcoactivator-1β, estrogen-related receptor family (ERRs), estrogen receptor α(ERα), mammalian target of rapamycin, c-Myc and PPARs.

Keywords: Cancer, energy metabolism, inhibitors, mitochondrial biogenesis, PGC-1α, tumor migration.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 11
ISSUE: 3
Year: 2016
Page: [332 - 341]
Pages: 10
DOI: 10.2174/1574892811666160418123628
Price: $65

Article Metrics

PDF: 83
HTML: 6
EPUB: 1
PRC: 1